Ids
stringlengths 36
36
| text
stringlengths 45
2.03k
| label
int64 0
1
|
|---|---|---|
a54e1dfa-3975-4dc6-8530-c0adc79b1b0d | primary trial: previous invasive breast cancer if diagnosed >5 years before entering study; secondary trial: Residence in Pilsen, Little Village, East Side or South Chicago; Agatha had her 50th birthday last week, she has a histologically confirmed adenocarcinoma of the breast, with no evidence of metastatic disease. She is eligible for the primary trial but not the secondary trial. | 1 |
a54e1dfa-3975-4dc6-8530-c0adc79b1b0d | primary trial: previous invasive breast cancer if diagnosed >5 years before entering study; secondary trial: No history of health volunteerism; Agatha had her 50th birthday last week, she has a histologically confirmed adenocarcinoma of the breast, with no evidence of metastatic disease. She is eligible for the primary trial but not the secondary trial. | 1 |
a54e1dfa-3975-4dc6-8530-c0adc79b1b0d | primary trial: previous invasive breast cancer if diagnosed >5 years before entering study; secondary trial: No history of breast cancer; and Agatha had her 50th birthday last week, she has a histologically confirmed adenocarcinoma of the breast, with no evidence of metastatic disease. She is eligible for the primary trial but not the secondary trial. | 1 |
a54e1dfa-3975-4dc6-8530-c0adc79b1b0d | primary trial: previous invasive breast cancer if diagnosed >5 years before entering study; secondary trial: Lack of a mammogram within the last two years Agatha had her 50th birthday last week, she has a histologically confirmed adenocarcinoma of the breast, with no evidence of metastatic disease. She is eligible for the primary trial but not the secondary trial. | 1 |
a54e1dfa-3975-4dc6-8530-c0adc79b1b0d | primary trial: previous invasive breast cancer if diagnosed >5 years before entering study; secondary trial: Not meeting all inclusion criteria; Agatha had her 50th birthday last week, she has a histologically confirmed adenocarcinoma of the breast, with no evidence of metastatic disease. She is eligible for the primary trial but not the secondary trial. | 1 |
a54e1dfa-3975-4dc6-8530-c0adc79b1b0d | primary trial: previous invasive breast cancer if diagnosed >5 years before entering study; secondary trial: Women will be excluded if they participated in formative focus groups Agatha had her 50th birthday last week, she has a histologically confirmed adenocarcinoma of the breast, with no evidence of metastatic disease. She is eligible for the primary trial but not the secondary trial. | 1 |
a54e1dfa-3975-4dc6-8530-c0adc79b1b0d | primary trial: no evidence of metastatic disease. secondary trial: Age 52-75 years old; Agatha had her 50th birthday last week, she has a histologically confirmed adenocarcinoma of the breast, with no evidence of metastatic disease. She is eligible for the primary trial but not the secondary trial. | 1 |
a54e1dfa-3975-4dc6-8530-c0adc79b1b0d | primary trial: no evidence of metastatic disease. secondary trial: Identification as Latina/Hispanic/Chicana female; Agatha had her 50th birthday last week, she has a histologically confirmed adenocarcinoma of the breast, with no evidence of metastatic disease. She is eligible for the primary trial but not the secondary trial. | 1 |
a54e1dfa-3975-4dc6-8530-c0adc79b1b0d | primary trial: no evidence of metastatic disease. secondary trial: Residence in Pilsen, Little Village, East Side or South Chicago; Agatha had her 50th birthday last week, she has a histologically confirmed adenocarcinoma of the breast, with no evidence of metastatic disease. She is eligible for the primary trial but not the secondary trial. | 1 |
a54e1dfa-3975-4dc6-8530-c0adc79b1b0d | primary trial: no evidence of metastatic disease. secondary trial: No history of health volunteerism; Agatha had her 50th birthday last week, she has a histologically confirmed adenocarcinoma of the breast, with no evidence of metastatic disease. She is eligible for the primary trial but not the secondary trial. | 1 |
a54e1dfa-3975-4dc6-8530-c0adc79b1b0d | primary trial: no evidence of metastatic disease. secondary trial: No history of breast cancer; and Agatha had her 50th birthday last week, she has a histologically confirmed adenocarcinoma of the breast, with no evidence of metastatic disease. She is eligible for the primary trial but not the secondary trial. | 1 |
a54e1dfa-3975-4dc6-8530-c0adc79b1b0d | primary trial: no evidence of metastatic disease. secondary trial: Lack of a mammogram within the last two years Agatha had her 50th birthday last week, she has a histologically confirmed adenocarcinoma of the breast, with no evidence of metastatic disease. She is eligible for the primary trial but not the secondary trial. | 1 |
a54e1dfa-3975-4dc6-8530-c0adc79b1b0d | primary trial: no evidence of metastatic disease. secondary trial: Not meeting all inclusion criteria; Agatha had her 50th birthday last week, she has a histologically confirmed adenocarcinoma of the breast, with no evidence of metastatic disease. She is eligible for the primary trial but not the secondary trial. | 1 |
a54e1dfa-3975-4dc6-8530-c0adc79b1b0d | primary trial: no evidence of metastatic disease. secondary trial: Women will be excluded if they participated in formative focus groups Agatha had her 50th birthday last week, she has a histologically confirmed adenocarcinoma of the breast, with no evidence of metastatic disease. She is eligible for the primary trial but not the secondary trial. | 1 |
a54e1dfa-3975-4dc6-8530-c0adc79b1b0d | primary trial: history of severe hypersensitivity reaction to Taxotere; secondary trial: Age 52-75 years old; Agatha had her 50th birthday last week, she has a histologically confirmed adenocarcinoma of the breast, with no evidence of metastatic disease. She is eligible for the primary trial but not the secondary trial. | 1 |
a54e1dfa-3975-4dc6-8530-c0adc79b1b0d | primary trial: history of severe hypersensitivity reaction to Taxotere; secondary trial: Identification as Latina/Hispanic/Chicana female; Agatha had her 50th birthday last week, she has a histologically confirmed adenocarcinoma of the breast, with no evidence of metastatic disease. She is eligible for the primary trial but not the secondary trial. | 1 |
a54e1dfa-3975-4dc6-8530-c0adc79b1b0d | primary trial: history of severe hypersensitivity reaction to Taxotere; secondary trial: Residence in Pilsen, Little Village, East Side or South Chicago; Agatha had her 50th birthday last week, she has a histologically confirmed adenocarcinoma of the breast, with no evidence of metastatic disease. She is eligible for the primary trial but not the secondary trial. | 1 |
a54e1dfa-3975-4dc6-8530-c0adc79b1b0d | primary trial: history of severe hypersensitivity reaction to Taxotere; secondary trial: No history of health volunteerism; Agatha had her 50th birthday last week, she has a histologically confirmed adenocarcinoma of the breast, with no evidence of metastatic disease. She is eligible for the primary trial but not the secondary trial. | 1 |
a54e1dfa-3975-4dc6-8530-c0adc79b1b0d | primary trial: history of severe hypersensitivity reaction to Taxotere; secondary trial: No history of breast cancer; and Agatha had her 50th birthday last week, she has a histologically confirmed adenocarcinoma of the breast, with no evidence of metastatic disease. She is eligible for the primary trial but not the secondary trial. | 1 |
a54e1dfa-3975-4dc6-8530-c0adc79b1b0d | primary trial: history of severe hypersensitivity reaction to Taxotere; secondary trial: Lack of a mammogram within the last two years Agatha had her 50th birthday last week, she has a histologically confirmed adenocarcinoma of the breast, with no evidence of metastatic disease. She is eligible for the primary trial but not the secondary trial. | 1 |
a54e1dfa-3975-4dc6-8530-c0adc79b1b0d | primary trial: history of severe hypersensitivity reaction to Taxotere; secondary trial: Not meeting all inclusion criteria; Agatha had her 50th birthday last week, she has a histologically confirmed adenocarcinoma of the breast, with no evidence of metastatic disease. She is eligible for the primary trial but not the secondary trial. | 1 |
a54e1dfa-3975-4dc6-8530-c0adc79b1b0d | primary trial: history of severe hypersensitivity reaction to Taxotere; secondary trial: Women will be excluded if they participated in formative focus groups Agatha had her 50th birthday last week, she has a histologically confirmed adenocarcinoma of the breast, with no evidence of metastatic disease. She is eligible for the primary trial but not the secondary trial. | 1 |
a54e1dfa-3975-4dc6-8530-c0adc79b1b0d | primary trial: previous treatment with anthracycline, anthracenedione (mitoxantrone), or taxane; secondary trial: Age 52-75 years old; Agatha had her 50th birthday last week, she has a histologically confirmed adenocarcinoma of the breast, with no evidence of metastatic disease. She is eligible for the primary trial but not the secondary trial. | 1 |
a54e1dfa-3975-4dc6-8530-c0adc79b1b0d | primary trial: previous treatment with anthracycline, anthracenedione (mitoxantrone), or taxane; secondary trial: Identification as Latina/Hispanic/Chicana female; Agatha had her 50th birthday last week, she has a histologically confirmed adenocarcinoma of the breast, with no evidence of metastatic disease. She is eligible for the primary trial but not the secondary trial. | 1 |
a54e1dfa-3975-4dc6-8530-c0adc79b1b0d | primary trial: previous treatment with anthracycline, anthracenedione (mitoxantrone), or taxane; secondary trial: Residence in Pilsen, Little Village, East Side or South Chicago; Agatha had her 50th birthday last week, she has a histologically confirmed adenocarcinoma of the breast, with no evidence of metastatic disease. She is eligible for the primary trial but not the secondary trial. | 1 |
a54e1dfa-3975-4dc6-8530-c0adc79b1b0d | primary trial: previous treatment with anthracycline, anthracenedione (mitoxantrone), or taxane; secondary trial: No history of health volunteerism; Agatha had her 50th birthday last week, she has a histologically confirmed adenocarcinoma of the breast, with no evidence of metastatic disease. She is eligible for the primary trial but not the secondary trial. | 1 |
a54e1dfa-3975-4dc6-8530-c0adc79b1b0d | primary trial: previous treatment with anthracycline, anthracenedione (mitoxantrone), or taxane; secondary trial: No history of breast cancer; and Agatha had her 50th birthday last week, she has a histologically confirmed adenocarcinoma of the breast, with no evidence of metastatic disease. She is eligible for the primary trial but not the secondary trial. | 1 |
a54e1dfa-3975-4dc6-8530-c0adc79b1b0d | primary trial: previous treatment with anthracycline, anthracenedione (mitoxantrone), or taxane; secondary trial: Lack of a mammogram within the last two years Agatha had her 50th birthday last week, she has a histologically confirmed adenocarcinoma of the breast, with no evidence of metastatic disease. She is eligible for the primary trial but not the secondary trial. | 1 |
a54e1dfa-3975-4dc6-8530-c0adc79b1b0d | primary trial: previous treatment with anthracycline, anthracenedione (mitoxantrone), or taxane; secondary trial: Not meeting all inclusion criteria; Agatha had her 50th birthday last week, she has a histologically confirmed adenocarcinoma of the breast, with no evidence of metastatic disease. She is eligible for the primary trial but not the secondary trial. | 1 |
a54e1dfa-3975-4dc6-8530-c0adc79b1b0d | primary trial: previous treatment with anthracycline, anthracenedione (mitoxantrone), or taxane; secondary trial: Women will be excluded if they participated in formative focus groups Agatha had her 50th birthday last week, she has a histologically confirmed adenocarcinoma of the breast, with no evidence of metastatic disease. She is eligible for the primary trial but not the secondary trial. | 1 |
a54e1dfa-3975-4dc6-8530-c0adc79b1b0d | primary trial: treatment with fluoropyrimidine (5-fluorouracil) within the last 5 years. secondary trial: Age 52-75 years old; Agatha had her 50th birthday last week, she has a histologically confirmed adenocarcinoma of the breast, with no evidence of metastatic disease. She is eligible for the primary trial but not the secondary trial. | 1 |
a54e1dfa-3975-4dc6-8530-c0adc79b1b0d | primary trial: treatment with fluoropyrimidine (5-fluorouracil) within the last 5 years. secondary trial: Identification as Latina/Hispanic/Chicana female; Agatha had her 50th birthday last week, she has a histologically confirmed adenocarcinoma of the breast, with no evidence of metastatic disease. She is eligible for the primary trial but not the secondary trial. | 1 |
a54e1dfa-3975-4dc6-8530-c0adc79b1b0d | primary trial: treatment with fluoropyrimidine (5-fluorouracil) within the last 5 years. secondary trial: Residence in Pilsen, Little Village, East Side or South Chicago; Agatha had her 50th birthday last week, she has a histologically confirmed adenocarcinoma of the breast, with no evidence of metastatic disease. She is eligible for the primary trial but not the secondary trial. | 1 |
a54e1dfa-3975-4dc6-8530-c0adc79b1b0d | primary trial: treatment with fluoropyrimidine (5-fluorouracil) within the last 5 years. secondary trial: No history of health volunteerism; Agatha had her 50th birthday last week, she has a histologically confirmed adenocarcinoma of the breast, with no evidence of metastatic disease. She is eligible for the primary trial but not the secondary trial. | 1 |
a54e1dfa-3975-4dc6-8530-c0adc79b1b0d | primary trial: treatment with fluoropyrimidine (5-fluorouracil) within the last 5 years. secondary trial: No history of breast cancer; and Agatha had her 50th birthday last week, she has a histologically confirmed adenocarcinoma of the breast, with no evidence of metastatic disease. She is eligible for the primary trial but not the secondary trial. | 1 |
a54e1dfa-3975-4dc6-8530-c0adc79b1b0d | primary trial: treatment with fluoropyrimidine (5-fluorouracil) within the last 5 years. secondary trial: Lack of a mammogram within the last two years Agatha had her 50th birthday last week, she has a histologically confirmed adenocarcinoma of the breast, with no evidence of metastatic disease. She is eligible for the primary trial but not the secondary trial. | 1 |
a54e1dfa-3975-4dc6-8530-c0adc79b1b0d | primary trial: treatment with fluoropyrimidine (5-fluorouracil) within the last 5 years. secondary trial: Not meeting all inclusion criteria; Agatha had her 50th birthday last week, she has a histologically confirmed adenocarcinoma of the breast, with no evidence of metastatic disease. She is eligible for the primary trial but not the secondary trial. | 1 |
a54e1dfa-3975-4dc6-8530-c0adc79b1b0d | primary trial: treatment with fluoropyrimidine (5-fluorouracil) within the last 5 years. secondary trial: Women will be excluded if they participated in formative focus groups Agatha had her 50th birthday last week, she has a histologically confirmed adenocarcinoma of the breast, with no evidence of metastatic disease. She is eligible for the primary trial but not the secondary trial. | 1 |
16dc5a77-5758-4d19-9801-6e9932d9fbc9 | Percentage of Participants by Preferred Method of Drug Administration several patients in cohort 1 of the primary trial Preferred oral tablets as a Method of Drug Administration. | 0 |
16dc5a77-5758-4d19-9801-6e9932d9fbc9 | The preferred method of drug administration (IV or SC Herceptin) was assessed in trial-specific telephone interviews with each study participant. Participants were asked, "All things considered, which method of administration did you prefer?" at the end of the crossover period (Week 24). The percentage of participants who preferred each method of drug administration was reported. several patients in cohort 1 of the primary trial Preferred oral tablets as a Method of Drug Administration. | 0 |
16dc5a77-5758-4d19-9801-6e9932d9fbc9 | Time frame: Week 24 several patients in cohort 1 of the primary trial Preferred oral tablets as a Method of Drug Administration. | 0 |
16dc5a77-5758-4d19-9801-6e9932d9fbc9 | Arm/Group Title: Cohort 1: SC (SID) Then IV Herceptin several patients in cohort 1 of the primary trial Preferred oral tablets as a Method of Drug Administration. | 0 |
16dc5a77-5758-4d19-9801-6e9932d9fbc9 | Arm/Group Description: Participants received Herceptin on Day 1 of each 3-week cycle for 18 cycles. During Cycles 1 to 4 of the crossover period, SC Herceptin was administered via SID, and during Cycles 5 to 8, IV Herceptin was given. In the continuation period, participants received IV Herceptin for up to 10 remaining cycles. Administration was performed by HCP. Those with at least 2 treatment cycles remaining of the 18-cycle treatment course after the crossover period were offered the opportunity to self-administer SC Herceptin via SID under the direction of a trained HCP. The SC dose was 600 mg for all cycles where SC Herceptin was given, and the IV dose was 6 mg/kg for all cycles where IV Herceptin was given. several patients in cohort 1 of the primary trial Preferred oral tablets as a Method of Drug Administration. | 0 |
16dc5a77-5758-4d19-9801-6e9932d9fbc9 | Overall Number of Participants Analyzed: 117 several patients in cohort 1 of the primary trial Preferred oral tablets as a Method of Drug Administration. | 0 |
16dc5a77-5758-4d19-9801-6e9932d9fbc9 | Measure Type: Number several patients in cohort 1 of the primary trial Preferred oral tablets as a Method of Drug Administration. | 0 |
16dc5a77-5758-4d19-9801-6e9932d9fbc9 | Unit of Measure: percentage of participants SC Herceptin: 95.7 several patients in cohort 1 of the primary trial Preferred oral tablets as a Method of Drug Administration. | 0 |
16dc5a77-5758-4d19-9801-6e9932d9fbc9 | IV Herceptin: 4.3 several patients in cohort 1 of the primary trial Preferred oral tablets as a Method of Drug Administration. | 0 |
16dc5a77-5758-4d19-9801-6e9932d9fbc9 | No Preference: 0.0 several patients in cohort 1 of the primary trial Preferred oral tablets as a Method of Drug Administration. | 0 |
16dc5a77-5758-4d19-9801-6e9932d9fbc9 | Arm/Group Title: Cohort 1: IV Then SC (SID) Herceptin several patients in cohort 1 of the primary trial Preferred oral tablets as a Method of Drug Administration. | 0 |
16dc5a77-5758-4d19-9801-6e9932d9fbc9 | Arm/Group Description: Participants received Herceptin on Day 1 of each 3-week cycle for 18 cycles. During Cycles 1 to 4 of the crossover period, IV Herceptin was given, and during Cycles 5 to 8, SC Herceptin was administered via SID. In the continuation period, participants received IV Herceptin for up to 10 remaining cycles. Administration was performed by HCP. Those with at least 2 treatment cycles remaining of the 18-cycle treatment course after the crossover period were offered the opportunity to self-administer SC Herceptin via SID under the direction of a trained HCP. The IV dose was a loading dose of 8 mg/kg in Cycle 1 for de novo participants who started Herceptin treatment in the study, and a dose of 6 mg/kg for all subsequent cycles where IV Herceptin was given and for non-de novo participants. The SC dose was 600 mg for all cycles where SC Herceptin was given. several patients in cohort 1 of the primary trial Preferred oral tablets as a Method of Drug Administration. | 0 |
16dc5a77-5758-4d19-9801-6e9932d9fbc9 | Overall Number of Participants Analyzed: 119 several patients in cohort 1 of the primary trial Preferred oral tablets as a Method of Drug Administration. | 0 |
16dc5a77-5758-4d19-9801-6e9932d9fbc9 | Measure Type: Number several patients in cohort 1 of the primary trial Preferred oral tablets as a Method of Drug Administration. | 0 |
16dc5a77-5758-4d19-9801-6e9932d9fbc9 | Unit of Measure: percentage of participants SC Herceptin: 87.4 several patients in cohort 1 of the primary trial Preferred oral tablets as a Method of Drug Administration. | 0 |
16dc5a77-5758-4d19-9801-6e9932d9fbc9 | IV Herceptin: 9.2 several patients in cohort 1 of the primary trial Preferred oral tablets as a Method of Drug Administration. | 0 |
16dc5a77-5758-4d19-9801-6e9932d9fbc9 | No Preference: 3.4 several patients in cohort 1 of the primary trial Preferred oral tablets as a Method of Drug Administration. | 0 |
2ed770a0-fe98-4029-9511-ad04a94a1a69 | primary trial: Total: 6 secondary trial: Total: 17/145 (11.72%) In the primary trial cohort 2 had more patients with Leukopenia than cohort 1, whereas in the secondary trial cohort 1 had more than cohort 2. Cohort 1 of the primary trial had the highest proportion of patients with leukopenia. | 0 |
2ed770a0-fe98-4029-9511-ad04a94a1a69 | primary trial: Total: 6 secondary trial: ANAEMIA 0/145 (0.00%) In the primary trial cohort 2 had more patients with Leukopenia than cohort 1, whereas in the secondary trial cohort 1 had more than cohort 2. Cohort 1 of the primary trial had the highest proportion of patients with leukopenia. | 0 |
2ed770a0-fe98-4029-9511-ad04a94a1a69 | primary trial: Total: 6 secondary trial: LEUKOPENIA 2/145 (1.38%) In the primary trial cohort 2 had more patients with Leukopenia than cohort 1, whereas in the secondary trial cohort 1 had more than cohort 2. Cohort 1 of the primary trial had the highest proportion of patients with leukopenia. | 0 |
2ed770a0-fe98-4029-9511-ad04a94a1a69 | primary trial: Total: 6 secondary trial: NEUTROPENIA 1/145 (0.69%) In the primary trial cohort 2 had more patients with Leukopenia than cohort 1, whereas in the secondary trial cohort 1 had more than cohort 2. Cohort 1 of the primary trial had the highest proportion of patients with leukopenia. | 0 |
2ed770a0-fe98-4029-9511-ad04a94a1a69 | primary trial: Total: 6 secondary trial: LEUKOCYTOSIS 1/145 (0.69%) In the primary trial cohort 2 had more patients with Leukopenia than cohort 1, whereas in the secondary trial cohort 1 had more than cohort 2. Cohort 1 of the primary trial had the highest proportion of patients with leukopenia. | 0 |
2ed770a0-fe98-4029-9511-ad04a94a1a69 | primary trial: Total: 6 secondary trial: THROMBOCYTOPENIA 1/145 (0.69%) In the primary trial cohort 2 had more patients with Leukopenia than cohort 1, whereas in the secondary trial cohort 1 had more than cohort 2. Cohort 1 of the primary trial had the highest proportion of patients with leukopenia. | 0 |
2ed770a0-fe98-4029-9511-ad04a94a1a69 | primary trial: Total: 6 secondary trial: FEBRILE NEUTROPENIA 1/145 (0.69%) In the primary trial cohort 2 had more patients with Leukopenia than cohort 1, whereas in the secondary trial cohort 1 had more than cohort 2. Cohort 1 of the primary trial had the highest proportion of patients with leukopenia. | 0 |
2ed770a0-fe98-4029-9511-ad04a94a1a69 | primary trial: Total: 6 secondary trial: THROMBOTIC THROMBOCYTOPENIC PURPURA 0/145 (0.00%) In the primary trial cohort 2 had more patients with Leukopenia than cohort 1, whereas in the secondary trial cohort 1 had more than cohort 2. Cohort 1 of the primary trial had the highest proportion of patients with leukopenia. | 0 |
2ed770a0-fe98-4029-9511-ad04a94a1a69 | primary trial: Total: 6 secondary trial: DISSEMINATED INTRAVASCULAR COAGULATION 0/145 (0.00%) In the primary trial cohort 2 had more patients with Leukopenia than cohort 1, whereas in the secondary trial cohort 1 had more than cohort 2. Cohort 1 of the primary trial had the highest proportion of patients with leukopenia. | 0 |
2ed770a0-fe98-4029-9511-ad04a94a1a69 | primary trial: Total: 6 secondary trial: CARDIAC FAILURE 1/145 (0.69%) In the primary trial cohort 2 had more patients with Leukopenia than cohort 1, whereas in the secondary trial cohort 1 had more than cohort 2. Cohort 1 of the primary trial had the highest proportion of patients with leukopenia. | 0 |
2ed770a0-fe98-4029-9511-ad04a94a1a69 | primary trial: Total: 6 secondary trial: ATRIAL FIBRILLATION 1/145 (0.69%) In the primary trial cohort 2 had more patients with Leukopenia than cohort 1, whereas in the secondary trial cohort 1 had more than cohort 2. Cohort 1 of the primary trial had the highest proportion of patients with leukopenia. | 0 |
2ed770a0-fe98-4029-9511-ad04a94a1a69 | primary trial: Total: 6 secondary trial: Total: 11/144 (7.64%) In the primary trial cohort 2 had more patients with Leukopenia than cohort 1, whereas in the secondary trial cohort 1 had more than cohort 2. Cohort 1 of the primary trial had the highest proportion of patients with leukopenia. | 0 |
2ed770a0-fe98-4029-9511-ad04a94a1a69 | primary trial: Total: 6 secondary trial: ANAEMIA 1/144 (0.69%) In the primary trial cohort 2 had more patients with Leukopenia than cohort 1, whereas in the secondary trial cohort 1 had more than cohort 2. Cohort 1 of the primary trial had the highest proportion of patients with leukopenia. | 0 |
2ed770a0-fe98-4029-9511-ad04a94a1a69 | primary trial: Total: 6 secondary trial: LEUKOPENIA 0/144 (0.00%) In the primary trial cohort 2 had more patients with Leukopenia than cohort 1, whereas in the secondary trial cohort 1 had more than cohort 2. Cohort 1 of the primary trial had the highest proportion of patients with leukopenia. | 0 |
2ed770a0-fe98-4029-9511-ad04a94a1a69 | primary trial: Total: 6 secondary trial: NEUTROPENIA 0/144 (0.00%) In the primary trial cohort 2 had more patients with Leukopenia than cohort 1, whereas in the secondary trial cohort 1 had more than cohort 2. Cohort 1 of the primary trial had the highest proportion of patients with leukopenia. | 0 |
2ed770a0-fe98-4029-9511-ad04a94a1a69 | primary trial: Total: 6 secondary trial: LEUKOCYTOSIS 0/144 (0.00%) In the primary trial cohort 2 had more patients with Leukopenia than cohort 1, whereas in the secondary trial cohort 1 had more than cohort 2. Cohort 1 of the primary trial had the highest proportion of patients with leukopenia. | 0 |
2ed770a0-fe98-4029-9511-ad04a94a1a69 | primary trial: Total: 6 secondary trial: THROMBOCYTOPENIA 0/144 (0.00%) In the primary trial cohort 2 had more patients with Leukopenia than cohort 1, whereas in the secondary trial cohort 1 had more than cohort 2. Cohort 1 of the primary trial had the highest proportion of patients with leukopenia. | 0 |
2ed770a0-fe98-4029-9511-ad04a94a1a69 | primary trial: Total: 6 secondary trial: FEBRILE NEUTROPENIA 1/144 (0.69%) In the primary trial cohort 2 had more patients with Leukopenia than cohort 1, whereas in the secondary trial cohort 1 had more than cohort 2. Cohort 1 of the primary trial had the highest proportion of patients with leukopenia. | 0 |
2ed770a0-fe98-4029-9511-ad04a94a1a69 | primary trial: Total: 6 secondary trial: THROMBOTIC THROMBOCYTOPENIC PURPURA 1/144 (0.69%) In the primary trial cohort 2 had more patients with Leukopenia than cohort 1, whereas in the secondary trial cohort 1 had more than cohort 2. Cohort 1 of the primary trial had the highest proportion of patients with leukopenia. | 0 |
2ed770a0-fe98-4029-9511-ad04a94a1a69 | primary trial: Total: 6 secondary trial: DISSEMINATED INTRAVASCULAR COAGULATION 1/144 (0.69%) In the primary trial cohort 2 had more patients with Leukopenia than cohort 1, whereas in the secondary trial cohort 1 had more than cohort 2. Cohort 1 of the primary trial had the highest proportion of patients with leukopenia. | 0 |
2ed770a0-fe98-4029-9511-ad04a94a1a69 | primary trial: Total: 6 secondary trial: CARDIAC FAILURE 0/144 (0.00%) In the primary trial cohort 2 had more patients with Leukopenia than cohort 1, whereas in the secondary trial cohort 1 had more than cohort 2. Cohort 1 of the primary trial had the highest proportion of patients with leukopenia. | 0 |
2ed770a0-fe98-4029-9511-ad04a94a1a69 | primary trial: Total: 6 secondary trial: ATRIAL FIBRILLATION 0/144 (0.00%) In the primary trial cohort 2 had more patients with Leukopenia than cohort 1, whereas in the secondary trial cohort 1 had more than cohort 2. Cohort 1 of the primary trial had the highest proportion of patients with leukopenia. | 0 |
2ed770a0-fe98-4029-9511-ad04a94a1a69 | primary trial: Agranulocytosis 0/42 (0.00%) secondary trial: Total: 17/145 (11.72%) In the primary trial cohort 2 had more patients with Leukopenia than cohort 1, whereas in the secondary trial cohort 1 had more than cohort 2. Cohort 1 of the primary trial had the highest proportion of patients with leukopenia. | 0 |
2ed770a0-fe98-4029-9511-ad04a94a1a69 | primary trial: Agranulocytosis 0/42 (0.00%) secondary trial: ANAEMIA 0/145 (0.00%) In the primary trial cohort 2 had more patients with Leukopenia than cohort 1, whereas in the secondary trial cohort 1 had more than cohort 2. Cohort 1 of the primary trial had the highest proportion of patients with leukopenia. | 0 |
2ed770a0-fe98-4029-9511-ad04a94a1a69 | primary trial: Agranulocytosis 0/42 (0.00%) secondary trial: LEUKOPENIA 2/145 (1.38%) In the primary trial cohort 2 had more patients with Leukopenia than cohort 1, whereas in the secondary trial cohort 1 had more than cohort 2. Cohort 1 of the primary trial had the highest proportion of patients with leukopenia. | 0 |
2ed770a0-fe98-4029-9511-ad04a94a1a69 | primary trial: Agranulocytosis 0/42 (0.00%) secondary trial: NEUTROPENIA 1/145 (0.69%) In the primary trial cohort 2 had more patients with Leukopenia than cohort 1, whereas in the secondary trial cohort 1 had more than cohort 2. Cohort 1 of the primary trial had the highest proportion of patients with leukopenia. | 0 |
2ed770a0-fe98-4029-9511-ad04a94a1a69 | primary trial: Agranulocytosis 0/42 (0.00%) secondary trial: LEUKOCYTOSIS 1/145 (0.69%) In the primary trial cohort 2 had more patients with Leukopenia than cohort 1, whereas in the secondary trial cohort 1 had more than cohort 2. Cohort 1 of the primary trial had the highest proportion of patients with leukopenia. | 0 |
2ed770a0-fe98-4029-9511-ad04a94a1a69 | primary trial: Agranulocytosis 0/42 (0.00%) secondary trial: THROMBOCYTOPENIA 1/145 (0.69%) In the primary trial cohort 2 had more patients with Leukopenia than cohort 1, whereas in the secondary trial cohort 1 had more than cohort 2. Cohort 1 of the primary trial had the highest proportion of patients with leukopenia. | 0 |
2ed770a0-fe98-4029-9511-ad04a94a1a69 | primary trial: Agranulocytosis 0/42 (0.00%) secondary trial: FEBRILE NEUTROPENIA 1/145 (0.69%) In the primary trial cohort 2 had more patients with Leukopenia than cohort 1, whereas in the secondary trial cohort 1 had more than cohort 2. Cohort 1 of the primary trial had the highest proportion of patients with leukopenia. | 0 |
2ed770a0-fe98-4029-9511-ad04a94a1a69 | primary trial: Agranulocytosis 0/42 (0.00%) secondary trial: THROMBOTIC THROMBOCYTOPENIC PURPURA 0/145 (0.00%) In the primary trial cohort 2 had more patients with Leukopenia than cohort 1, whereas in the secondary trial cohort 1 had more than cohort 2. Cohort 1 of the primary trial had the highest proportion of patients with leukopenia. | 0 |
2ed770a0-fe98-4029-9511-ad04a94a1a69 | primary trial: Agranulocytosis 0/42 (0.00%) secondary trial: DISSEMINATED INTRAVASCULAR COAGULATION 0/145 (0.00%) In the primary trial cohort 2 had more patients with Leukopenia than cohort 1, whereas in the secondary trial cohort 1 had more than cohort 2. Cohort 1 of the primary trial had the highest proportion of patients with leukopenia. | 0 |
2ed770a0-fe98-4029-9511-ad04a94a1a69 | primary trial: Agranulocytosis 0/42 (0.00%) secondary trial: CARDIAC FAILURE 1/145 (0.69%) In the primary trial cohort 2 had more patients with Leukopenia than cohort 1, whereas in the secondary trial cohort 1 had more than cohort 2. Cohort 1 of the primary trial had the highest proportion of patients with leukopenia. | 0 |
2ed770a0-fe98-4029-9511-ad04a94a1a69 | primary trial: Agranulocytosis 0/42 (0.00%) secondary trial: ATRIAL FIBRILLATION 1/145 (0.69%) In the primary trial cohort 2 had more patients with Leukopenia than cohort 1, whereas in the secondary trial cohort 1 had more than cohort 2. Cohort 1 of the primary trial had the highest proportion of patients with leukopenia. | 0 |
2ed770a0-fe98-4029-9511-ad04a94a1a69 | primary trial: Agranulocytosis 0/42 (0.00%) secondary trial: Total: 11/144 (7.64%) In the primary trial cohort 2 had more patients with Leukopenia than cohort 1, whereas in the secondary trial cohort 1 had more than cohort 2. Cohort 1 of the primary trial had the highest proportion of patients with leukopenia. | 0 |
2ed770a0-fe98-4029-9511-ad04a94a1a69 | primary trial: Agranulocytosis 0/42 (0.00%) secondary trial: ANAEMIA 1/144 (0.69%) In the primary trial cohort 2 had more patients with Leukopenia than cohort 1, whereas in the secondary trial cohort 1 had more than cohort 2. Cohort 1 of the primary trial had the highest proportion of patients with leukopenia. | 0 |
2ed770a0-fe98-4029-9511-ad04a94a1a69 | primary trial: Agranulocytosis 0/42 (0.00%) secondary trial: LEUKOPENIA 0/144 (0.00%) In the primary trial cohort 2 had more patients with Leukopenia than cohort 1, whereas in the secondary trial cohort 1 had more than cohort 2. Cohort 1 of the primary trial had the highest proportion of patients with leukopenia. | 0 |
2ed770a0-fe98-4029-9511-ad04a94a1a69 | primary trial: Agranulocytosis 0/42 (0.00%) secondary trial: NEUTROPENIA 0/144 (0.00%) In the primary trial cohort 2 had more patients with Leukopenia than cohort 1, whereas in the secondary trial cohort 1 had more than cohort 2. Cohort 1 of the primary trial had the highest proportion of patients with leukopenia. | 0 |
2ed770a0-fe98-4029-9511-ad04a94a1a69 | primary trial: Agranulocytosis 0/42 (0.00%) secondary trial: LEUKOCYTOSIS 0/144 (0.00%) In the primary trial cohort 2 had more patients with Leukopenia than cohort 1, whereas in the secondary trial cohort 1 had more than cohort 2. Cohort 1 of the primary trial had the highest proportion of patients with leukopenia. | 0 |
2ed770a0-fe98-4029-9511-ad04a94a1a69 | primary trial: Agranulocytosis 0/42 (0.00%) secondary trial: THROMBOCYTOPENIA 0/144 (0.00%) In the primary trial cohort 2 had more patients with Leukopenia than cohort 1, whereas in the secondary trial cohort 1 had more than cohort 2. Cohort 1 of the primary trial had the highest proportion of patients with leukopenia. | 0 |
2ed770a0-fe98-4029-9511-ad04a94a1a69 | primary trial: Agranulocytosis 0/42 (0.00%) secondary trial: FEBRILE NEUTROPENIA 1/144 (0.69%) In the primary trial cohort 2 had more patients with Leukopenia than cohort 1, whereas in the secondary trial cohort 1 had more than cohort 2. Cohort 1 of the primary trial had the highest proportion of patients with leukopenia. | 0 |
2ed770a0-fe98-4029-9511-ad04a94a1a69 | primary trial: Agranulocytosis 0/42 (0.00%) secondary trial: THROMBOTIC THROMBOCYTOPENIC PURPURA 1/144 (0.69%) In the primary trial cohort 2 had more patients with Leukopenia than cohort 1, whereas in the secondary trial cohort 1 had more than cohort 2. Cohort 1 of the primary trial had the highest proportion of patients with leukopenia. | 0 |
2ed770a0-fe98-4029-9511-ad04a94a1a69 | primary trial: Agranulocytosis 0/42 (0.00%) secondary trial: DISSEMINATED INTRAVASCULAR COAGULATION 1/144 (0.69%) In the primary trial cohort 2 had more patients with Leukopenia than cohort 1, whereas in the secondary trial cohort 1 had more than cohort 2. Cohort 1 of the primary trial had the highest proportion of patients with leukopenia. | 0 |
2ed770a0-fe98-4029-9511-ad04a94a1a69 | primary trial: Agranulocytosis 0/42 (0.00%) secondary trial: CARDIAC FAILURE 0/144 (0.00%) In the primary trial cohort 2 had more patients with Leukopenia than cohort 1, whereas in the secondary trial cohort 1 had more than cohort 2. Cohort 1 of the primary trial had the highest proportion of patients with leukopenia. | 0 |
2ed770a0-fe98-4029-9511-ad04a94a1a69 | primary trial: Agranulocytosis 0/42 (0.00%) secondary trial: ATRIAL FIBRILLATION 0/144 (0.00%) In the primary trial cohort 2 had more patients with Leukopenia than cohort 1, whereas in the secondary trial cohort 1 had more than cohort 2. Cohort 1 of the primary trial had the highest proportion of patients with leukopenia. | 0 |
2ed770a0-fe98-4029-9511-ad04a94a1a69 | primary trial: Anaemia 2/42 (4.76%) secondary trial: Total: 17/145 (11.72%) In the primary trial cohort 2 had more patients with Leukopenia than cohort 1, whereas in the secondary trial cohort 1 had more than cohort 2. Cohort 1 of the primary trial had the highest proportion of patients with leukopenia. | 0 |